Literature DB >> 12427418

Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study.

Arnaud Lazarus1, Jean Varin, Dominique Babuty, Frédéric Anselme, Joel Coste, Denis Duboc.   

Abstract

OBJECTIVES: We hypothesized that pacemaker (PM) implantation in patients with myotonic dystrophy (MD) with a prolonged HV interval, even asymptomatic, may protect them against sudden death related to atrioventricular (AV) block. We sought to prospectively document the true incidence of AV block episodes in this high-risk population and accurately trace, in the long term, by the PM, the occurrence of arrhythmias that may remain undetected during conventional follow-up.
BACKGROUND: Myotonic dystrophy is associated with a high risk of sudden death, commonly attributed to AV block or ventricular arrhythmias, but cardiac pacing is only recommended as a secondary prevention.
METHODS: Patients with MD with an HV interval > or =70 ms, even in the absence of related symptoms, prospectively received a cardiac PM, including an algorithm capable of diagnosing episodes of bradycardia and tachyarrhythmias.
RESULTS: The population consisted of 49 patients (45.5 +/- 8.9 years old) followed for 53.5 +/- 27.2 months. Paroxysmal arrhythmias were recorded in 41 patients (83.7%), consisting of complete AV block (n = 21), sino-atrial block (n = 4), or atrial (n = 25) or ventricular (n = 13) tachyarrhythmias. No patient died of AV block during follow-up, but 10 deaths occurred, 4 of them sudden. An arrhythmic cause could be excluded by postmortem PM interrogation in two cases of typical sudden death.
CONCLUSIONS: Arrhythmias are common in patients with MD with infrahisian conduction abnormalities. The prophylactic implantation of a pacing system when the HV interval is > or =70 ms seems appropriate. The PM protects the patient against the clinical consequences of paroxysmal profound bradycardia and facilitates the diagnosis and management of frequent paroxysmal tachyarrhythmias.

Entities:  

Mesh:

Year:  2002        PMID: 12427418     DOI: 10.1016/s0735-1097(02)02339-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

Review 2.  Arrhythmias in the muscular dystrophies.

Authors:  Archana Rajdev; William J Groh
Journal:  Card Electrophysiol Clin       Date:  2015-03-29

3.  A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre.

Authors:  Elisabetta Bucci; Marco Testa; Loretta Licchelli; Alessandra Frattari; Nadia Attalla El Halabieh; Erica Gabriele; Giulia Pignatelli; Tiziana De Santis; Laura Fionda; Fiammetta Vanoli; Stefania Morino; Matteo Garibaldi; Antonella Di Pasquale; Nicola Vanacore; Annalisa Botta; Giovanni Antonini
Journal:  J Neurol       Date:  2018-02-10       Impact factor: 4.849

4.  QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance.

Authors:  Saman Nazarian; David A Bluemke; Kathryn R Wagner; Menekhem M Zviman; Evrim Turkbey; Brian S Caffo; Monda Shehata; David Edwards; Barbara Butcher; Hugh Calkins; Ronald D Berger; Henry R Halperin; Gordon F Tomaselli
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

5.  The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.

Authors:  Auinash Kalsotra; Ravi K Singh; Priyatansh Gurha; Amanda J Ward; Chad J Creighton; Thomas A Cooper
Journal:  Cell Rep       Date:  2014-01-09       Impact factor: 9.423

6.  Aberrant Expression of a Non-muscle RBFOX2 Isoform Triggers Cardiac Conduction Defects in Myotonic Dystrophy.

Authors:  Chaitali Misra; Sushant Bangru; Feikai Lin; Kin Lam; Sara N Koenig; Ellen R Lubbers; Jamila Hedhli; Nathaniel P Murphy; Darren J Parker; Lawrence W Dobrucki; Thomas A Cooper; Emad Tajkhorshid; Peter J Mohler; Auinash Kalsotra
Journal:  Dev Cell       Date:  2020-02-27       Impact factor: 12.270

7.  Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy.

Authors:  Frédérique Rau; Fernande Freyermuth; Charlotte Fugier; Jean-Philippe Villemin; Marie-Christine Fischer; Bernard Jost; Doulaye Dembele; Geneviève Gourdon; Annie Nicole; Denis Duboc; Karim Wahbi; John W Day; Harutoshi Fujimura; Masanori P Takahashi; Didier Auboeuf; Natacha Dreumont; Denis Furling; Nicolas Charlet-Berguerand
Journal:  Nat Struct Mol Biol       Date:  2011-06-19       Impact factor: 15.369

8.  Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy.

Authors:  Saman Nazarian; Kathryn R Wagner; Brian S Caffo; Gordon F Tomaselli
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-14       Impact factor: 1.976

9.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

10.  Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.

Authors:  Anna Rago; Andrea Antonio Papa; Giulia Arena; Marco Mosella; Antonio Cassese; Alberto Palladino; Paolo Golino
Journal:  Acta Myol       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.